HDA UK MEDIA AND POLITICAL BULLETIN – 6 July 2017
The Labour Party frontbench has urged the Prime Minister to drop her red line opposition to membership of the European Court of Justice, in a letter to the Financial Times. The letter, signed by Shadow Brexit Secretary Keir Starmer, and Shadow Health Secretary Jon Ashworth, urged continued EU regulation for the health sciences, including remaining members of the European Medicines Agency. Industry leaders are also convinced that participation in at least the first stage of the drug approval process would be beneficial, as reported in the Financial Times on July 3rd. The preferred setup at the moment is that testing continues at the EMA, with separate but identical regulatory proposals be sent to London and Brussels for final signoff.
The Value of Traceability
Controlled Experiments, Erin England, 5 July, 2017
In an op-ed piece, the US-based scientific magazine Controlled Experiments reminded its readers that the traceability of pharmaceutical drugs is “increasingly vital to the integrity of pharmaceutical products”. Coming on the heels of the 2 year count-down for the Falsified Medicines Directive (FMD), this piece demonstrates that traceability has become a regulatory watchword in the industry. Nearly every functional area of the pharmaceutical supply chain is now “emphasizing traceability”. The key to this process is calibration and measurement, to ensure that standards are consistent across the supply chain. The article concluded by noting that pharmaceutical companies are now experiencing more pressure from regulators to maintain this consistency, either through the FMD or recent regulations from the FDA.
There is no parliamentary coverage.
The Value of Traceability
Controlled Experiments, Erin England, 5 July, 2017
In the pharmaceutical industry, the traceability of prescription drugs is increasingly vital to the integrity of pharmaceutical products. By providing more end-to-end visibility into pharma supply chains, companies can better trace serialized products from wholesalers to end customers, enhancing the reliability of supply deliveries while also offering a way to detect counterfeit drugs and track diverted products.
With greater recognition of the importance of traceability, increased demand is being placed on the pharma industry to improve the robustness of traceability requirements. The Drug Supply Chain Security Act will eventually require serialization and item-level traceability of prescription drugs, enabling supply-chain partners to track product ownership to the manufacturer or re-packager.
Beyond the pharmaceutical supply chain, nearly every functional area within the pharmaceutical facility is now beginning to emphasize traceability. This includes cleaning validation studies and water quality monitoring, where thorough traceability requirements help ensure the accuracy, performance, and reliability of critical total organic carbon (TOC) measurements. The TOC instruments used for these measurements have become a widespread best practice throughout the pharmaceutical industry, providing a simple yet effective way to ensure that processes are in control.
Measurement traceability, as applied to TOC analyzers, refers to an unbroken chain of comparisons relating an instrument’s measurements to a known standard. For industries that rely on TOC measurements, calibration and verification are the most commonly used methods to align an instrument with a traceable standard for determining precision and accuracy.
Measurement failures and Out-of-Specifications
Out-of-Specification (OOS) results refer to test results that fall outside established specifications. When an OOS result occurs, FDA regulations require that an investigation be conducted to determine the cause and that a written record of the investigation be made, including conclusions and follow-up. Whether a sample preparation or an actual process issue, there is a limited amount of time before costs begin to rise as the root cause investigation is conducted.
Although an OOS may seem inconsequential, it can lead to production delays and question the validity of data. An OOS can also compound the risks associated with instrument certification, the standard that is used, or even the person who is performing the work. Cases where data drift out of tolerance can severely affect business. As such, metrology groups are under pressure to quickly resolve these situations and re-certify an analyzer for further use.
Improved traceability can shorten the resolution of an OSS and details or reports supplied by vendors to help quickly close out non-conformances are invaluable. In particular, a failure analysis report (FAR) is an important tool in traceability.
For example, an OSS investigation would be triggered if a pharmaceutical company reports a TOC value exceeding their limit for a cleaning validation (CV) study. The company may troubleshoot this measurement and investigate if the instrument is flawed, the vial contaminated, or if the sample does indeed have a higher organic concentration. If the components of the measure are supplied by a single vendor, the vendor provides a FAR, which cross references the lot numbers of the company’s:
• Vials used to collect the CV samples;
• Standards bracketing the TOC samples against any other reports covering the same lot (providing full visibility into the quality checks associated with empty vials);
• Reference materials; and
• TOC instrument health.
If these elements are validated through a FAR, then the company can be confident that the measurement does accurately reflect an increase in TOC, which can help resolve the OOS investigation efficiently.
Why do accreditations matter?
ISO Guide 34 and ISO/IEC 17025 accreditations ensure that manufactured reference materials used for equipment calibrations are consistently produced, controlled, and audited to robust quality standards. ISO Guide 34 provides the highest level of quality assurance and certifies that a manufacturer’s processes comply with strict guidelines and include all contributing factors to uncertainty. ISO/IEC 17025 certifies the reliability of the testing performed in conjunction with reference material production and confirms the manufacturer’s ability to produce precise, accurate test and calibration data with the instruments used to qualify each production lot.
Without these accreditations (whether purchased from a supplier or made in-house), pharmaceutical manufacturers cannot be confident in the consistency and, thus, the traceability of standards.
Analytical Instruments: Full in-house traceability
Pharmaceutical companies face mounting pressures for increased traceability within their supply chains. This includes the need to close out non-conformances and OSSs quickly. Because of this, traceability of every material and instrument used in processes becomes important. Analytical Instruments addresses these concerns by offering:
• The highest combined accreditation standard in the industry (ISO Guide 34 and ISO/IEC 17025 accredited for the production and testing of TOC and conductivity standards).
• Full traceability of both standards and vials (due to cleaning its own vials used in standards production).
• Full visibility and traceability of standards and reference materials, and vials and instrument health, including the availability of Failure Analysis Reports.
Complete traceability of reference materials, vials, and instruments helps pharmaceutical companies efficiently “close the loop” on TOC out-of-specifications … reducing risks, increasing data quality, and ensuring a reliable and accurate total TOC measurement solution.
From Factory to Pharmacy
As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.See the Infographic
Apply to become a Member
Membership of the HDA guarantees your organisation:
- Access to leading policy and industry forums of debate and discussion
- Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
- Representation on HDA working parties, including the Members’ Liaison Group
- A daily Political and Media Bulletin and HDA Newsletters
- Access to HDA policy documents and all sections of the HDA website
- Branding and marketing opportunities